Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology
ClinicalTrials.gov Identifier:
NCT00054418
First received: February 5, 2003
Last updated: July 12, 2016
Last verified: July 2016